Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877265 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2605541 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01877265 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01877265, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study looks at the amount of LY2605541 in the body after it is injected under the skin. The study has 3 periods, each lasting 10 days. Each participant will receive one injection in each period. At least 14 days will pass between each injection.
Interventions
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877265
The ClinicalTrials.gov registry entry for NCT01877265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2605541 is the first listed.
NCT01877265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877265 about?
NCT01877265 is a clinical study titled "A Study of LY2605541 in Healthy Participants". This study looks at the amount of LY2605541 in the body after it is injected under the skin. The study has 3 periods, each lasting 10 days. Each participant will receive one injection in each period. At least 14 days will pass between each injection.
What is the current status of trial NCT01877265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01877265?
The interventions under investigation include: LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01877265?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.